Mabtech

NOVEMBER 2019

Sector: Healthcare
Service: M&A

Our role

Exclusive financial adviser to the owners of Mabtech on the sale to IK Partners

Target

Mabtech was founded in 1986 and has gained worldwide recognition for its high quality monoclonal antibodies and technical capabilities and is viewed as a pioneer within the growing detection platform techniques ELISpot and FluoroSpot

Buyer

IK Partners is Pan-European private equity firm focused on investments in the Nordics, DACH region, France and Benelux. Since 1989, IK Partners has raised more than EUR 10 billion of capital and invested in over 125 European companies. In connection with the transaction, Merieux Equity Partners acquired a minority stake alongside IK Partners' fund

Previous Next View all transactions

Words from our client

“ We would like to thank Evli that ensured a highly professional and successful sales process – both management and shareholders are very happy with the outcome. The Evli team provided excellent guidance throughout the entire process with their commitment, integrity, and senior attention – all with a humble approach and true passion for getting a successful deal in place." Staffan Paulie, Chairman and co-founder of Mabtech

Mabtech

Our role

Target

Buyer

Words from our client

Evli Corporate Finance AB